BTIG downgraded Simulations Plus (SLP) to Neutral from Buy without a price target Despite early signs of stabilization in parts of the bio-pharma services market, Simulations Plus continues to face pressure, with declining recent revenues, a muted FY26 growth outlook, and a disappointing $77M write-down tied in part to a recent acquisition, the analyst tells investors in a research note Ongoing demand softness, limited visibility on a recovery, and multiple 2026 headwinds temper the firm’s confidence in a near-term turnaround.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLP:
- Simulations Plus Announces New Executive Appointments
- FDA guides on streamlined nonclinical monoclonal antibody safety studies
- Positive Outlook for Simulations Plus Amid Strong Financial Performance and Strategic Industry Alignment
- Simulations Plus: Strategic Investments and Market Positioning Drive Buy Recommendation
- Simulations Plus Reports Q4 2025 Financial Results